Fluticasone furoate +Umeclidinium + Vilanterol  belongs to the therapeutic class of  Bronchodilator combination

Fluticasone furoate +Umeclidinium + Vilanterol treats chronic obstructive pulmonary disease (COPD) and asthma in adults. It is a long-term maintenance treatment that helps to improve lung function and reduce symptoms, such as wheezing, shortness of breath, and chest tightness. 

Fluticasone furoate +Umeclidinium + Vilanterol is administered by inhalation only. It is not intended to be swallowed or injected. Its dosage depends on the individual's needs and preferences.

Fluticasone furoate +Umeclidinium + Vilanterol can cause side effects, including mild ones like dry mouth, headache, and sore throat, and more serious ones like fungal infections, pneumonia, and sudden breathing problems.

Sudden breathing problems can occur immediately after Fluticasone furoate +Umeclidinium + Vilanterol. Effects on the heart like increased blood pressure, a fast or irregular heartbeat, awareness of heartbeat, and chest pain can also occur.

If you have a history of heart problems, high blood pressure, or diabetes, talk to your doctor before using Fluticasone furoate +Umeclidinium + Vilanterol. Use it exactly as prescribed by your doctor. Take only what is prescribed, and do not take it more often than prescribed.

Do not use if you are allergic to Fluticasone furoate +Umeclidinium + Vilanterol or any other ingredients. Do not use it for the relief of sudden breathing problems. It is not a rescue inhaler and should not be used to treat acute asthma attacks or COPD exacerbations. Tell your doctor about all your medications, including prescription, over-the-counter, herbal supplements, and vitamins. Use it exactly as prescribed by your doctor. Take only what is prescribed, and only take it sometimes. If you experience serious side effects like sudden breathing problems, chest pain, or a fast or irregular heartbeat, stop taking it and seek medical attention immediately. Rinse your mouth with water after using this medication.

1. EMA (2018). Trelegy Ellipta - European Medicines Agency. European Medicines Agency. Available at  [Accessed 11th Oct 2023].   https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta#:~:text=Trelegy%20Ellipta%20is%20a%20medicine
2. HIGHLIGHTS OF PRESCRIBING INFORMATION. (2019). [online] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209482s003lbl.pdf    [Accessed 21 Jan. 2023].
3. reference.medscape.com. (n.d.). Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol inhaled) dosing, indications, interactions, adverse effects, and more. [online] Available at: https://reference.medscape.com/drug/trelegy-ellipta-fluticasone-furoate-umeclidinium-bromide-vilanterol-inhaled-1000165#4  [Accessed 11th Oct 2023].
4. medlineplus.gov. (2020). Fluticasone, Umeclidinium, and Vilanterol Oral Inhalation: MedlinePlus Drug Information. [online] Available at: https://medlineplus.gov/druginfo/meds/a618017.html  [Accessed 11th Oct 2023].
5. www.trelegy.com. (2022). Treatment Option | TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol). [online] Available at: https://www.trelegy.com/  [Accessed 11th Oct 2023].

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.